Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.23.1
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Basic and diluted numerator:          
Net loss attributable to iBio, Inc. $ (6,279) $ (6,746)   $ (24,379) $ (19,125)
Preferred stock dividends - iBio CMO Preferred Tracking Stock 0 0   0 (88)
Net loss available to iBio, Inc. stockholders (6,279) (6,746)   (24,379) (19,213)
Loss from discontinued operations (1,015) (5,644)   (34,598) (14,124)
Net loss available to iBio, Inc. stockholders $ (7,294) $ (12,390)   $ (58,977) $ (33,337)
Basic and diluted denominator:          
Weighted-average common shares outstanding - basic 13,184 8,719   10,592 8,719
Weighted-average common shares outstanding - diluted 13,184 8,719 8,719 10,592 8,719
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.47) $ (0.77)   $ (2.30) $ (2.20)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.47) (0.77) $ (2.20) (2.30) (2.20)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (0.08) (0.65)   (3.27) (1.62)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (0.08) (0.65) (1.62) (3.27) (1.62)
Per share amount basic (0.55) (1.42)   (5.57) (3.82)
Per share amount diluted $ (0.55) $ (1.42) $ (3.82) $ (5.57) $ (3.82)